- About Us
- Nano-Social Network
- Nano Consulting
- My Account
November 30th, 2007
Biotech Corp acquires exclusive worldwide license to nanotechnology platform
Malaysian Biotechnology Corporation (Biotech Corp) has acquired its first technology acquisition from Nanobiotix, a French start-up company, for an undisclosed amount.
Nanobiotix develops nanotechnology applications for cancer therapy. However, Biotech Corp is licensing the nanotechnology platform for non-cancer purposes.
Nanobiotix founder and chief executive officer Dr Laurent Levy said this would allow it to concentrate its resources on oncology applications while expanding its potential pipeline into non-cancer areas via Biotech Corp.
The license will provide access to the application of high-level nanotechnology in the country, said BioTech Corp chief executive officer Datuk Iskandar Mizal Mahmood at the launch on Nov 30.
|Related News Press|
In-cell molecular sieve from protein crystal February 14th, 2017
Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative February 13th, 2017
Particles from outer space are wreaking low-grade havoc on personal electronics February 19th, 2017
Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016
Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016
NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016